122
Participants
Start Date
April 3, 2018
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2028
GM-CSF + Naxitamab
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
RECRUITING
Rigshospitalet, Copenhagen
ACTIVE_NOT_RECRUITING
Memorial Sloan Kettering Cancer Center, New York
WITHDRAWN
Hopital pour enfants de la Timone, Marseille
RECRUITING
Giannina Gaslini Hospital, Genoa
RECRUITING
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
RECRUITING
Hospital Infantil Universitario Niño Jesús, Madrid
WITHDRAWN
University of Florida, Gainesville
WITHDRAWN
Nationwide Children's Hospital, Columbus
RECRUITING
Hospital Universitario y Politécnico La Fe, Valencia
ACTIVE_NOT_RECRUITING
Riley Hospital for Children, Indianapolis
WITHDRAWN
University of Chicago, Chicago
WITHDRAWN
M.D. Anderson Cancer Center, Houston
RECRUITING
Tata Memorial Centre, Mumbai
RECRUITING
The Hospital for Sick Children, Toronto
RECRUITING
University Medical Center Hamburg-Eppendorf, Hamburg
RECRUITING
Johannes Gutenberg-Universität, Mainz
RECRUITING
University Hospital Regensburg, Regensburg
RECRUITING
Hong Kong Children's Hospital, Hong Kong
ACTIVE_NOT_RECRUITING
Queen Mary Hospital, Hong Kong
RECRUITING
Ospedale Pediatrico Bambino Gesù, Rome
RECRUITING
Hospital Universitario Virgen Del Rocío, Seville
RECRUITING
Hospital Sant Joan de Déu, Barcelona
RECRUITING
The Royal Glasgow Children's Hospital, Glasgow
RECRUITING
Leeds General Infirmary, Leeds
WITHDRAWN
The Royal Marsden, London
RECRUITING
University Hospital Southampton, Southampton
Lead Sponsor
Y-mAbs Therapeutics
INDUSTRY